teriflunomide

a leflunomide metabolite

Also Known As:

(2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide; 2-hydroxyethylidene-cyanoacetic acid-4-trifluoromethyl anilide; A 1726; A 771726; A-771726; A77 1726; A771726; Aubagio; HMR-1726; HMR1726; RS 61980

Networked: 442 relevant articles (40 outcomes, 122 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kappos, Ludwig: 25 articles (10/2022 - 10/2011)
2.	Freedman, Mark S: 24 articles (01/2021 - 10/2011)
3.	Miller, Aaron E: 20 articles (10/2022 - 11/2012)
4.	Truffinet, Philippe: 20 articles (01/2022 - 10/2011)
5.	Comi, Giancarlo: 16 articles (11/2020 - 10/2011)
6.	Benamor, Myriam: 15 articles (12/2021 - 08/2013)
7.	Wolinsky, Jerry S: 14 articles (11/2020 - 10/2011)
8.	Olsson, Tomas P: 11 articles (11/2020 - 10/2011)
9.	O'Connor, Paul W: 11 articles (01/2018 - 09/2012)
10.	Bar-Or, Amit: 10 articles (01/2022 - 09/2012)

Related Diseases

1.	Multiple Sclerosis 06/01/2019 - "Based on extensive evidence from randomized controlled trials (RCTs) and the real-world setting, oral teriflunomide is an effective and generally well tolerated treatment in patients with relapsing multiple sclerosis (MS), with these benefits maintained during long-term treatment (≥ 10 years) and no new safety signals identified. " 03/28/2006 - "Oral teriflunomide was effective in reducing MRI lesions and was well tolerated in patients with relapsing multiple sclerosis." 05/01/2015 - "Teriflunomide is a new oral disease-modifying drug (DMD), recently approved for the first-line treatment of relapsing multiple sclerosis (MS). " 01/01/2023 - "The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS). " 12/01/2021 - "The TERIKIDS study examined the safety and efficacy of teriflunomide in children with relapsing multiple sclerosis. "
2.	Relapsing-Remitting Multiple Sclerosis 12/01/2023 - "Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study." 10/01/2023 - "Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study." 01/01/2023 - "The aim of this study was to characterise adult Portuguese relapsing-remitting multiple sclerosis patients treated with teriflunomide in routine clinical practice concerning their quality of life, comorbidities, treatment effectiveness, satisfaction, compliance and safety. " 01/01/2023 - "The aim was to study brain innate immune cell activation in teriflunomide-treated patients with relapsing-remitting multiple sclerosis. " 09/01/2022 - "Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece."
3.	Rheumatoid Arthritis 01/01/2023 - "The objective of the study was to investigate the relation between plasma-concentration of teriflunomide and disease-activity in rheumatoid arthritis. " 05/15/2011 - "The procedure was applied to assess total and free plasma concentrations of teriflunomide in patients with rheumatoid arthritis. " 05/15/2011 - "Therefore, we aimed to develop and validate an LC-MS/MS method for the measurement of teriflunomide, and use it to determine the total and free teriflunomide concentration in patients with rheumatoid arthritis. " 04/01/2003 - "To analyse in vitro the possible anti-inflammatory effects exerted by A77 1726, on cultured macrophages, obtained from the synovial tissues of patients with rheumatoid arthritis (RA). " 01/01/2019 - "Teriflunomide is primarily used for the treatment of rheumatoid arthritis and multiple sclerosis.A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated to quantify the drug teriflunomide over a concentration range of 5 ng/mL-200 μg/mL in serum or plasma. "
4.	COVID-19 08/01/2021 - "descriptive, retrospective, multicentre, study that included MS patients receiving teriflunomide who developed COVID-19, with clinical follow-up at reference MS centres, also listed in a nationwide registry. " 08/01/2021 - "Eighteen MS patients on teriflunomide treatment, from eight MS centres developed COVID-19. " 08/01/2021 - "We report COVID-19 presentation, course and outcomes in teriflunomide-treated MS patients in Argentina. " 02/01/2021 - "Teriflunomide was continued during the entire course of SARS-CoV-2 infection in all patients except for two. " 02/01/2021 - "Apart from the present report, since February 2020, five papers have been published describing 14 MS patients who developed SARS-CoV-2 infection during teriflunomide treatment. "
5.	Demyelinating Diseases (Demyelinating Disease) 01/01/2019 - "Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study." 12/01/2017 - "Treatment of Theiler's virus-induced demyelinating disease with teriflunomide." 12/01/2016 - "Our results identify specific GALT-derived CD39+ Treg cells as a mechanism of action that may contribute to the efficacy of teriflunomide during CNS inflammatory demyelination and as an oral therapeutic in relapsing multiple sclerosis." 10/01/2013 - "The mechanism behind reduced axonal loss and improved motor function may be primarily the reduced inflammation and consequent demyelination observed in these animals through the known effects of teriflunomide on impairing proliferation of stimulated T cells. " 09/10/2021 - "Most of these disease-modifying therapies, except teriflunomide, carry the risk of progressive multifocal leukoencephalopathy (PML), a severely debilitating, often fatal virus-induced demyelinating disease. "

Related Drugs and Biologics

1.	Dimethyl Fumarate
2.	Leflunomide (Arava)
3.	Fingolimod Hydrochloride (FTY720)
4.	ofatumumab
5.	Dihydroorotate Dehydrogenase
6.	Glatiramer Acetate (Copaxone)
7.	Natalizumab (Tysabri)
8.	Immunologic Factors (Immunomodulators)
9.	ponesimod
10.	ublituximab

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Time-to-Treatment
4.	Immunomodulation
5.	Precision Medicine